The E1 protein is a multifunctional, origin-binding helicase that is essential for replication of papillomaviruses. Recently, bovine papillomavirus E1 was shown to be post-translationally modified by the addition of the SUMO-1 polypeptide. Here we show that the site of sumoylation maps to lysine residue 514. This lysine and the flanking sequences are well conserved in human papillomavirus (HPV) E1 proteins. Both HPV1a and HPV18 E1 proteins are substrates for sumoylation in vitro, which is consistent with this modification being a general property of E1 proteins. Mutations, which impair the sumoylation of bovine papillomavirus E1, prevent normal nuclear accumulation of E1 with a concomitant loss of replication capacity. These results suggest that sumoylation plays a role in nuclear transport and could regulate the E1 replication function by controlling access to the nuclear replication domains.
Bovine papillomavirus (BPV)
1 E1 protein is the major initiator protein for viral DNA replication and thus plays a critical role in the establishment of episomal viral genomes in the host cell nucleus (1) . E1 and E2 proteins are the only two viral proteins required to replicate the viral genome in vivo, whereas the rest of the replication machinery is provided by the host cell (2, 3) . E1 is a DNA helicase that binds to specific sequences in the viral origin and unwinds the viral DNA for initiation of replication (4, 5) . Purified E1 protein can initiate in vitro viral replication without the support of the E2 protein (6) . However, the interaction of E1 with E2 protein promotes specific binding and assembly of E1 protein on the viral origin to form an active initiation complex (7, 8) . Additional functions of E1 include recruiting cellular replication factors, such as the DNA polymerase ␣ and replication protein A (9 -11) . E1 also interacts with histone H1 (12) and SW1/SNF5 (13) , suggesting that E1 plays a role in chromatin remodeling at the viral origin.
Recently, we demonstrated that BPV E1 protein is posttranslationally modified by a novel process known as sumoylation (14) . Sumoylation involves the covalent attachment of the small ubiquitin-related proteins (SUMO-1, -2, or -3) to target substrates (15) . Sumoylation is achieved by a multistep process in a manner that is analogous to ubiquitinylation (reviewed in Ref. 16) . SUMO is first activated by a heterodimeric enzyme termed Aos1/Uba2, and then the activated SUMO is covalently transferred to the SUMO-specific conjugating enzyme Ubc9 via a thioester linkage (17) . Ubc9 physically interacts with various substrates and transfers SUMO to one or more lysine residues in the target protein. Unlike ubiquitinylation in which the primary function is targeting proteins for degradation, the effects of sumoylation are more substrate-specific and can result in alterations in function (18 -20) , stability (21) , or intracellular location (22) (23) (24) (25) of the modified protein. For BPV E1, a mutant unable to interact with Ubc9 showed altered intranuclear distribution (14) . As BPV E1 is the first known viral replicator modified by SUMO-1, the biochemical and functional characterizations of the SUMO-conjugated E1 protein are likely to provide a paradigm for other viral and/or cellular replicative proteins.
To further understand the role of E1 sumoylation, this study identified the major SUMO-1 attachment site in the BPV E1 protein and evaluated the functional properties of mutants defective in sumoylation. E1 mutants defective in Ubc9 interaction or lacking the SUMO-1 attachment lysine all demonstrated impaired replication as a consequence of defective nuclear localization. Furthermore, two HPV E1 proteins were also shown to be substrates for sumoylation in vitro, suggesting that this is a general feature of E1 proteins. Thus, the covalent modification of E1 proteins by SUMO-1 represents a potential novel mechanism to regulate E1 replication activity by controlling entry into the nucleus.
EXPERIMENTAL PROCEDURES
Antibodies, Plasmids, and Mutagenesis-Monoclonal anti-SUMO-1 antibody (21C7) was purchased from Zymed Laboratories, Inc. (South San Francisco, CA), and the rabbit polyclonal anti-E1 antibody was raised against amino acids 2-75 of BPV E1 (26) . Vectors for in vitro translation of full-length and truncated forms of BPV E1 and vectors for HPV1a E1 and HPV18 E1 were described previously (14, 27, 28) . For in vivo experiments, NH 2 -terminally His-tagged E1 was expressed from pcDNA4/MAX (Invitrogen, Carlsbad, CA), untagged E1 was expressed from pCGE1 (29) for replication assays, and GFP-E1 was expressed from pEGFP-C2 (CLONTECH, Palo Alto, CA). All site-directed mutagenesis was carried out using the QuikChange polymerase chain reaction-based mutagenesis kit (Stratagene, La Jolla, CA), and the mutant plasmids were fully sequenced to exclude the possibility of second site mutations. Human SUMO-1 and the Ubc9 expression vectors were described previously (14) .
Yeast Two-hybrid Analysis-Vectors and procedures for the twohybrid experiments were reported by Rangasamy and Wilson (14) .
Purification of Proteins-His-tagged SUMO-1 and glutathione Stransferase-Ubc9 were expressed in Escherichia coli BL21(DE3) and purified as described by Gonzalez et al. (30) . As a source of the SUMOactivating enzyme, protein extracts were prepared from confluent NIH 3T3 cells as described by Schwarz et al. (31) . An extract prepared from ten 100-mm plates of cells was loaded on a 1-ml Q-Sepharose column (Amersham Pharmacia Biotech) in 20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM dithiothreitol. Bound protein was eluted with 400 mM NaCl equilibrated with 20 mM Tris-HCl, pH 7.5, 0.5 mM dithiothreitol, dialyzed against 20 mM Tris-HCl, pH 7.5, 0.5 mM dithiothreitol, concentrated with a Centricon-30, and used in the in vitro sumoylation assay.
In Vitro Sumoylation Assay-The in vitro SUMO-1 conjugation assay was carried out as described recently (14) except that the HeLa cell extract was replaced with the partially purified SUMO-activating enzyme. 2 l of in vitro translated E1 protein were incubated with 20 g of the Q-Sepharose fraction (as noted earlier) containing SUMO-1-activating enzymes Aos1/Uba2, 7 g of purified SUMO-1, and 1 g of Ubc9 in a 20-l reaction with an ATP regenerating buffer (50 mM Tris-HCl, pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM creatine phosphate, 3 units/ml creatine kinase, and 1 unit/ml inorganic pyrophosphatase). After 2 h at 30°C, reactions were terminated by the addition of SDSsample buffer and heated at 70°C for 4 min. Reaction products were analyzed on SDS-polyacrylamide gels, and radioactively labeled bands were visualized and quantitated with a PhosphorImager (Molecular Dynamics).
Immunoprecipitation and Western Blotting-COS-1 cells grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 0.1% non-essential amino acids (Life Technologies, Inc.) were transfected with LipofectAMINE PLUS reagents according to the manufacturer's instructions (Life Technologies, Inc.). A total of 10 g of plasmid DNA consisting of 4 g of the His 6 -E1 vector encoding wildtype or mutant E1 proteins, 4 g of the SUMO-1 vector, and 2 g of the Ubc9 vector were co-transfected into 1 ϫ 10 7 cells in 75-cm 2 flasks. Control transfections used 4 g of the His 6 -E1 plus 6 g of the empty pcDNA 3.1 vector. 36 h after transfection, the COS-1 cells were lysed and immunoprecipitated as described previously using 5 g of anti-E1 antibody (14) . Alternatively, E1 in the extracts was purified on nickelaffinity columns (Qiagen) as specified by the manufacturer. Immunoprecipitates and column eluates were subjected to SDS-8% polyacrylamide gels, and the proteins were transferred to a nylon membrane. Western blotting was performed following standard procedures with anti-E1 and anti-SUMO-1 antibodies. The proteins were detected using a chemiluminescence reagent, Super Signal Dura (Pierce).
Transient in Vivo Replication Assay-Approximately 1.4 ϫ 10 6 Chinese hamster ovary cells were seeded into 60-mm dishes the day before transfection. The cells were transfected with LipofectAMINE PLUS reagents and had received 0.1 g of pCGE2 (3), 1 g of pBOR (BPV origin in pUC19) (32) or pUC19 (nonorigin), and 1 g of the respective pCGE1 expressing wild-type or mutant E1 proteins. After transfection, cells were trypsinized, and an equal number of cells was seeded into three 60-mm dishes. The cells were lysed at various times post-transfection, and the samples were digested for at least 16 h with a mixture of 15 units each of DpnI and HindIII and 16 g of RNase A. After digestion, Southern blots were performed according to standard procedures with radiolabeled pBOR DNA, and the blots were visualized and quantitated with a PhosphorImager.
Fluorescence Microscopy-COS-1 cells were grown on four-well chamber slides (Nunc, Naperville, Ill), and 0.5 ϫ 10 4 cells/chamber were transfected with 250 ng of pGFP-E1 (either wild-type or mutant E1) DNA using LipofectAMINE PLUS reagent. After 24 h, cells were fixed with 2% paraformaldehyde in phosphate-buffered saline for 15 min at room temperature. The fixed cells were washed twice in phosphatebuffered saline and mounted in 90% glycerol in phosphate-buffered saline containing 0.1% p-phenylenediamine. GFP was visualized on a Nikon Eclipse E800 microscope combined with an Ultima Z confocal laser microscope with an oil immersion ϫ 40 objective lens and appropriate filter. For E1 protein quantification, 1 ϫ 10 5 cells were seeded onto 16-well tissue culture plates and transfected with 1 g of either wild-type or mutant pGFP-E1. Transfected cells were directly lysed with SDS-sample buffer and analyzed by Western blotting using anti-E1 antibody as noted earlier.
RESULTS

Requirements for SUMO-1 Conjugation of E1-The BPV E1
protein interacts with the Ubc9-conjugating enzyme and is modified by the addition of SUMO-1 both in vitro and in vivo (14) . As there are reports that some sumoylated proteins interact directly with SUMO-1 in the absence of Ubc9 (33, 34), we examined the ability of E1 to interact with SUMO-1 in the same manner. However, in the two-hybrid assay the interaction of E1 and SUMO-1 was modest compared with E1/Ubc9 or Ubc9/SUMO-1 (Fig. 1A) . Furthermore, we could not detect an E1⅐SUMO-1 complex in vitro using a glutathione S-transferase pulldown assay (data not shown). Based on these observations, we believe it is unlikely that SUMO-1 interacts directly with E1. The apparent interaction in the two-hybrid system probably represents a low level of covalent attachment of SUMO-1 to E1 protein via the endogenous yeast homolog of hUbc9 (31) rather than a noncovalent association.
Our previous in vitro assay for E1 sumoylation used a crude HeLa cell extract as a source of SUMO-1-activating enzymes, but independent extracts were variable in activity perhaps because of different ratios of activating to desumoylating enzymes. To provide a more defined system for additional studies, a partially purified activating enzyme complex (31) was used in the current studies. The two most prominent products of the purification were proteins with apparent molecular masses of 40 and 90 kDa, consistent with the subunit sizes of the heterodimeric Aos1/Uba2 (Fig. 1B) . As noted before, sumoylation of E1 required the addition of SUMO-1 and Ubc9 as well as the activating enzyme component (Fig. 1C) , confirming that an authentic sumoylation process had been recapitulated.
Identification of the E1 Sumoylation Site-The presence of a single SUMO-1-modified species of E1 in vitro and the apparent molecular mass of this sumoylated E1 form are consistent with the addition of a single SUMO-1 moiety. To map the region of the E1 protein where SUMO-1 is conjugated, truncated forms of E1 protein were evaluated for sumoylation capacity in vitro ( Fig. 2A) . Truncations containing the NH 2 -terminal 312 or 459 amino acids of E1 were incapable of being sumoylated. In contrast, the COOH-terminal portion of E1 from residues 315 to 605 was effectively sumoylated, indicating that the COOH terminus of E1 contains all the information necessary for E1 to be recognized by the SUMO-1 conjugation system. Because E1 1-459 interacts effectively with Ubc9 (14) , its inability to be sumoylated suggests that the actual site of addition is downstream between residues 460 and 605.
A short consensus sequence (L/I)KXE has been described, which accounts for the SUMO-1 acceptor site in most of the known SUMO-1 substrates (reviewed in Ref. 16 ). The BPV E1 sequence was searched for lysines present in this consensus or close matches, and four lysines were identified as possible sumoylation sites: Lys-89, Lys-155, Lys-288, and Lys-514.
Whereas only Lys-514 was consistent with our truncation mapping data, each of the four residues was mutated independently in the context of full-length E1, and the mutant proteins were tested for in vitro sumoylation (Fig. 2B) . The E1 protein containing the conservative K514R substitution was unable to be sumoylated. In contrast, no effect on sumoylation was observed with mutations at Lys-89, Lys-155, or Lys-288. Thus, lysine 514 is most probably the residue where SUMO-1 attachment occurs, confirming the importance of this region identified by the truncation analysis. The similarity between this region of E1 and two other known sumoylation sites is shown in Fig. 2D .
In a previous study (14), we reported that the Leu-Lys motif at positions 420 and 421 of the E1 protein is critical for Ubc9 binding and that mutation of this motif drastically impairs the ability of E1 to bind Ubc9 protein. The inability to interact effectively with Ubc9 should eliminate or reduce sumoylation, and this was tested in the in vitro assay (Fig. 2C) . No sumoylation of the L420P/K421A double mutant was detectable, whereas the L420I/K421A mutant was weakly sumoylated to approximately 10 -20% of the wild-type level. The residual sumoylation of the Ile-Ala mutant probably reflects a slight retention of Ubc9 interaction ability because of the more conservative amino acid substitutions. In contrast, the Pro-Ala mutant probably disrupts not only critical contact residues but also is more likely to alter the overall secondary structure of this region, resulting in complete loss of Ubc9 binding.
Sumoylation of HPV E1 Proteins-A previous study on human papillomavirus 16 (HPV16) E1 reported an interaction with Ubc9 in a yeast two-hybrid system, but no data were presented concerning sumoylation (35) . Examination of 30 HPV E1 protein sequences chosen at random (data not shown) revealed that 86% maintained a lysine at the position equivalent to BPV E1 residue 514 and that all retained the XPXL motif COOH-terminal to the lysine position (see motif in Fig.  2D ). To confirm that other E1 proteins can undergo SUMO-1 modification, we tested two different HPV E1 proteins in the in vitro conjugation assay (Fig. 3) . A truncated p53 protein (amino acids 72-390) (18) and BPV E1 were used as the positive controls for SUMO-1 modification. Incubation of both HPV1a E1 and HPV18 E1 with the complete sumoylation reaction resulted in the appearance of a higher molecular weight species that was consistent with the addition of SUMO-1. Sumoylation of both cutaneous and mucosal type HPV E1 proteins is consistent with this post-translational modification being a common feature of E1 proteins.
Sumoylation of E1 in Vivo-To establish that the in vitro results are an accurate representation of the situation in vivo, the BPV E1 mutants defective for Ubc9 interaction or lacking the SUMO-1 conjugation site were expressed in COS-1 cells. E1 was immunoprecipitated and analyzed by Western blotting with both anti-E1 and anti-SUMO-1 antibodies to determine the extent of sumoylation. As previously reported (14) , two species of wild-type E1 were detected with anti-E1, a major
FIG. 2. Mapping the site of sumoylation on E1.
A, in vitro translated full-length and truncated E1 proteins were incubated with or without the complete sumoylation assay mix and analyzed as in Fig. 1C . The subscript numbers refer to the E1 amino acids present in each polypeptide. Sumoylated products are indicated with an *. B, lysine substitution mutants of E1 were produced and analyzed for in vitro sumoylation as in A. C, two E1 double mutants of the Leu-Lys motif at residues 420 and 421 were assayed for in vitro sumoylation as in A. D, comparison of the sequence contexts of sumoylated lysine residues in BPV E1, PML, and inhibitor B (IB).
FIG. 3. In vitro sumoylation of HPV E1 proteins.
In vitro translated p53, BPV E1, HPV1a E1, and HPV18 E1 were tested for in vitro sumoylation as in Fig. 2A . Sumoylated products are indicated with an *.
form at ϳ82 kDa corresponding to full-length E1 and a minor form at ϳ102 kDa (Fig. 4, upper panel) . Reprobing the blot with anti-SUMO-1 confirmed that this minor band contained SUMO-1. Consistent with the in vitro results, neither the L420P/K421A mutant nor the K514R mutant was sumoylated in vivo. In addition, sumoylated E1 was not detected for the L420I/K421A mutant. However, since the E1 L420I/K421A mutant protein was poorly sumoylated in vitro, it is likely that similar low levels of sumoylation in vivo were below our detection limit. As an alternative approach to immunoprecipitation, these experiments were repeated using nickel-affinity chromatography for the recovery of E1 because the E1 expression vectors used in Fig. 4 produced His-tagged E1. The results obtained were identical to the immunoprecipitation data, and sumoylation of the L420I/K421A mutant was still not detected (data not shown).
Effect of SUMO-1 Modification on the Replication Activity of E1-To obtain insight into the biological role of SUMO-1 modification of E1, we used a triple plasmid in vivo replication assay to compare the replication activity of wild-type E1 with the replication activity of the Ubc9-binding deficient mutants and two different substitution mutants at the Lys-514 SUMO-1 conjugation site (Fig. 5A) . The E1 L420I/K421A mutant exhibited a 60% reduction in replication activity, whereas the mutant E1 L420P/K421A was completely unable to support the replication of the origin plasmid. Similarly, neither of the E1 proteins with substitutions at the sumoylation site was able to support any detectable replication activity. These replication defects were not attributable to decreased intracellular levels of the mutant proteins because all were expressed at comparable amounts (Fig. 5B, data not shown) (14) . Thus, compared with wild-type E1, mutants with defective sumoylation were significantly impaired for replication function.
Sumoylation Affects the Subcellular Localization of E1 Protein-It was recently shown that the sumoylation of PML correlates with the formation of nuclear bodies (25, 36, 37) , whereas the conjugation of SUMO-1 to RanGAP1 is important for its targeting to the nuclear pore complexes (23, 24) . Therefore, we tested whether sumoylation might influence the subcellular localization of E1 protein. To address this question, wild-type and mutant GFP-E1 fusion constructs were expressed in COS-1 cells, and the distribution of expressed E1 was analyzed by fluorescence confocal microscopy. In wild-type GFP-E1 transfected cells, E1 accumulated in intranuclear foci or speckles in addition to a diffuse nucleoplasmic distribution with little or no cytoplasmic staining (Fig. 6, A and B) . In contrast, the Ubc9-binding, defective E1 mutants, L420P/ K421A and L420I/K421A, exhibited predominantly cytoplasmic distribution (Fig. 6, C-F) ; a strong cytoplasmic signal was detected in at least 70% of the cells, and for L420P/K421A, the remaining cells exhibited diffuse nuclear staining either without any speckles or with a small number of clumps around the nuclear periphery. For GFP-E1 L420I/K421A, there was a punctate accumulation of E1 within the nucleus in less than 20% of the cells; however, the number and size of the speckles were less than those observed for wild-type E1, and the majority of E1 was still found in the cytoplasmic face of the nuclear rim (Fig. 6, C and D) . Likewise, the SUMO-1 site-defective mutant E1 K514R was unable to localize to the nucleus and, instead, primarily accumulated in the cytoplasmic region of the nuclear rim (Fig. 6, G and H) . Consistent with the Western blot data (Fig. 5) , the amounts of mutant E1 proteins detected by fluorescence did not appear to be significantly different from wild-type E1, so it is unlikely that this factor accounts for the altered intracellular distributions. Thus, the difference in the accumulation patterns demonstrates that SUMO-1 modifica -FIG. 4 . In vivo sumoylation of wild-type and mutant E1 proteins. COS-1 cells were transfected with the wild-type or mutant E1 expression vectors indicated above the lanes. Lanes marked with a ϩ also received expression vectors for Ubc9 and SUMO-1. Lanes marked with a Ϫ had the Ubc9 and SUMO-1 vectors replaced with an equal amount of the empty parental expression vector. At 36 h post-transfection, cell lysates were prepared and immunoprecipitated with anti-E1 antibodies. Precipitates were analyzed by SDS-8% polyacrylamide gel electrophoresis and were Western-blotted with anti-E1 antibodies (upper panel). Subsequently, the blot was stripped and reprobed with anti-SUMO-1 antibodies (lower panel).
FIG. 5. Triple plasmid transient in vivo replication assay. A,
Chinese hamster ovary cells were transfected with expression vectors for wild-type E1 or the various mutants indicated above the lanes. All transfections also received an E2 expression vector and either the origin-containing pBOR plasmid (lanes 3-17) or the control pUC19 plasmid (lanes 1 and 2) . At the indicated hours post-transfection, cells were harvested, and plasmid replications were assayed as described under "Experimental Procedures." Lanes 18 and 19 contain 10 and 100 pg, respectively, of linearized pBOR DNA as a marker for the position of replicated plasmid DNA. B, parallel cultures transfected with expression vectors for wild-type E1 or the K514R mutant were harvested at the times indicated. Total cell lysates were directly assayed by Western blotting with an anti-E1 antibody.
tion of E1 protein is required for proper localization of E1 within the nucleus. The intermediate phenotype of the L420I/ K421A mutant probably reflects a modest residual ability to interact with Ubc9, leading to a low level of sumoylation and subsequent deposition in the nucleus. DISCUSSION BPV E1 is a multifunctional nuclear protein that is essential for viral DNA replication. E1 specifically interacts with the host cell enzyme Ubc9, leading to post-translation modification of E1 by the addition of a SUMO-1 moiety (14) . The data presented here extend this observation by identifying the site of SUMO-1 addition and by evaluating the functional effects of sumoylation. Similar to many other SUMO-1 substrates (16), BPV E1 is modified by the addition of SUMO-1 to a single lysine residue 514. Substitution mutation of this target lysine residue totally abolished E1 sumoylation in vitro and in vivo. Consistent with the high conservation among HPV E1 proteins of BPV E1 lysine 514 and its flanking sequences, HPV1a and HPV18 E1 proteins were sumoylated in vitro. Although the actual site of sumoylation in the HPV E1 proteins has not yet been determined, these results imply that sumoylation will be a general feature of E1 proteins. Interestingly, the SUMO-1 conjugation site of E1 lacks the glutamic acid residue typically found at two residues COOH-terminal to the target lysine (16) . Instead, this position is a proline followed by another proline and then by two leucines. This KXPXLL motif is also present in one of the sumoylation sites of PML and may represent an alternative recognition motif for SUMO-1 conjugation.
Sumoylation appears to be a novel post-translational regulatory mechanism capable of modulating stability (21) , activity (18 -20) , or intracellular location (22-25) of various proteins. Analysis of E1 mutants defective for sumoylation has not demonstrated any overall effect on intracellular levels of E1 protein, although there are two possible caveats to our studies. First, the in vivo experiments were all done with overexpression vectors, which may override normal controls on E1 steady state levels. Second, there could be subtle changes in E1 levels during cell cycle stages that may not be apparent in unsynchronized cultures especially with protein overexpression. Consequently, any effect of sumoylation on E1 stability will need further evaluation.
In contrast to the apparent lack of effect on E1 levels, impaired sumoylation correlated with defective replication of a BPV origin plasmid in vivo. Three E1 mutants, L420P/K421A, K514A, and K514R, that were completely defective for sumoylation in vitro and in vivo demonstrated no replication in vivo. A fourth mutant, L420I/K421A, was weakly sumoylated in vitro and retained partial replication activity in vivo. Similarly, L420P/K421A, K514A, and K514R were all severely defective for intranuclear accumulation, whereas E1 L420I/K421A displayed an intermediate phenotype with some resemblance to the wild-type pattern although with quantitatively much reduced accumulation in the speckles and foci. Similar nuclear localization defects have been seen for SUMO-1 site mutants of PML and homeodomain-interacting protein kinase 2 (22, 25) . Therefore, we conclude from our data that SUMO-1 modification of E1 is required for normal intranuclear accumulation and distribution of the E1 proteins and that the inability of the mutant E1 proteins to reach their required levels or sites in the nucleus resulted in the replication defect. Although the identity of the nuclear speckles and foci we observed with wild-type E1 has not been determined, at least some of these E1 accumulations likely represent the viral "replication compartments" that are localized in close proximity to ND10s (38, 39) . Thus, the subcellular partitioning of E1 through post-translational modification by SUMO-1 may be of general importance as an additional mechanism for the regulation of viral replication by the host cell. Whether or not the mutations tested also have any direct impact on E1 replicative functions outside of preventing nuclear localization has not yet been determined. Likewise, the direct effect of the SUMO-1 moiety on wild-type E1 functions remains to be investigated.
The mechanism by which sumoylation is required for intranuclear accumulation of E1 is unknown, although it may involve transport through the nuclear pores in as much of the unsumoylated E1 accumulated at the nuclear periphery. Because it is unlikely that all nuclear proteins are sumoylated, a generic requirement for sumoylation as part of the typical nuclear pore transport process seems doubtful. Intriguingly, E1 contains a nuclear localization signal (NLS)-like sequence, RKHK (residues 505-508), that is just NH 2 -terminal to the sumoylation site at residue 514. Whereas E1 is known to possess a bipartite NLS in the NH 2 -terminal region that is required for nuclear uptake (40, 41) , the possible contribution of this second potential site has not been evaluated. Sumoylation near this second site may be required to facilitate passage through the nuclear pore. Alternatively, E1 may possess a region inhibitory to nuclear transport that is counteracted by the addition of SUMO-1. Consistent with this second possibility, a small E1-derived polypeptide containing the bipartite NLS efficiently directed fused ␤-galactosidase to the nucleus (41) . This result indicates that there is no sumoylation requirement for the nuclear uptake function of the known NLS when it is separated from the bulk of the E1 sequences as would be expected if inhibitory sequences were located elsewhere in the protein. Whereas these two models are appealing in their simplicity, other mechanisms are also possible, and further studies will be needed to resolve the role of sumoylation in nuclear uptake. Nonetheless, the E1 protein provides a relatively well 40 (A, C, E, G) or ϫ 60 (B,  D, F, H) magnification.
